← All trials
NCT04973930
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Dec 31, 2023
- First posted
- Jul 22, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversityCollaborator
- Columbia UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.